

THE BEST OF GI, ONCOLOGY

PROGRAMA

28 y 29 de abril 2022

Hotel Best Western Marina Las Condes, Santiago de Chile

JUEVES 28 de abril		
08:15	Inscripciones y registro	
Módulo: CÁNCER DE ESTÓMAGO Y ESÓFAGO		Coordinan: Dres.: Consuelo Díaz, México - Marcelo Garrido, Chile.
08:40	Cortina de espera	
09:00	Terapias en cáncer unión gastro-esofágica	Dr. Jorge Gallardo, Chile
09:15	In the DESTINY gastric trastuzumab-deruxtecan	Dr. Fernando Hurtado de Mendoza, Perú
09:30	Overview of what is new in radiotherapy	Dr. Rodrigo Barrientos, Chile
09:45	Does mucinous gastric cancer deserve a special approach?	Dr. Ernesto Maturana, Chile
10:00	ctDNA applications in advanced disease: Biomarker testing, monitoring, resistance	Dr. Mauricio Rivas, Chile
10:15	The microbiome in gastric cancer	Dr. Ignacio Retamal, Chile
10:30	Visita stands y café	
Módulo: CÁNCER DE HÍGADO - VÍA BILIAR		Coordinan: Dres.: Mónica Ahumada, Chile - Dr. Gerardo Arroyo, Argentina
11:00	Adjuvant S-1 versus observation in curatively resected biliary cancer	Dr. Hugo Freire, Chile
11:15	Current landscape in biliary tract cancer	Dr. Javier Anabalón, Chile
11:30	Overcoming emerging drug resistance in intrahepatic cholangiocarcinoma	Dr. Arnaldo Marín, Chile
11:45	Combination systemic therapies in hepatocellular carcinoma: Now what?	Dr. Luis Villanueva, Chile
12:00	Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial.	Dr. Federico Esteso, Argentina
12:15	Integrating new targeted therapy into local-regional treatment of localized intrahepatic cholangiocarcinoma.	Dra. Bárbara Núñez, Chile
12:30	Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.	Dr. Jaime González, Chile
13:00 - 13:30	Bloque Simposio AstraZeneca "Cáncer páncreas y BRCA , estudio POLO"	Dr. Juan Manuel O'Connor, Argentina
Módulo: TUMORES NEURO-ENDOCRINOS Y CÁNCER DE PÁNCREAS		Coordinan: Dres.: Florencia McAllister, USA - Mauricio Mahave, Chile.
14:30	Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan clinical oncology group study (JCOG1213).	Dra. María Nieto Coronel, Bolivia
14:45	LBA56 - Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study Tomas Seufferlein ESMO 2021	Dra. Anelisa Coutinho, Brasil
15:00	KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation	Dr. Cristóbal Sanhueza, Chile
15:15	Inmunoterapia en cáncer de páncreas	Dra. Florencia McAllister, MD Anderson, EEUU.
15:30	Novedades en el tratamiento de la enfermedad avanzada. 2021/2022 Nuevos ensayos clínicos en curso	Dra. Marcela Carballido, Argentina
15:50	Debate: Tratamiento estándar en cáncer resecable es la cirugía seguida de adyuvancia, vs neoadyuvancia en cáncer páncreas resecable	Dr. Michell Butts, Chile Dr. Jorge Gallardo, Chile
16:10	Visita stands y café	
Módulo: CÁNCER DE COLON Y CÁNCER DE RECTO		Coordinan: Dres.: Germán Calderillo, México - Cristián Caglevic, Chile.
16:40	Short-course radiotherapy versus long-course chemoradiation	Dr. Pablo González, Chile
16:55	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study	Dr. Jorge León, Perú
17:10	Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.	Dr. René Muñoz, Ecuador
17:25	A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).	Dr. Diego Bustos, Chile
17:40	Gran debate: La terapia en primera línea cáncer colon Et IV, MSI-H sigue siendo Quimioterapia Vs Inmunoterapia	Dra. Erika Ruiz, México Dra. Marylere Herrera, México
18:10	Bloque Simposio Bristol Myers Squibb - BMS "Cáncer Gástrico primera línea"	Dr. Marcelo Garrido, Chile

SIMPOSIO DE INMUNO-ONCOLOGÍA | FLASCA

PROGRAMA PRELIMINAR

VIERNES 29 de abril		
08:15	Inscripciones y registro	
INMUNOTERAPIA CÁNCERES GASTROINTESTINALES 1		Presiden: Dres.: Olga Barajas, Chile - Miguel Fodor, Chile.
08:45	Cortina de espera	
09:00	CM 577. Adjuvant NIVO in resected EC and GEJC following neoadjuvant CRT	Dr. Francisco Inataf, Chile
09:15	First-line nivolumab plus chemotherapy vs chemotherapy in advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma: expanded efficacy and safety data from CheckMate 649	Dr. Patricio Yáñez, Chile
09:30	Challenges in patient selection for immunotherapy - testing	Dr. Juan Manuel O'Connor, Argentina
09:45	First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.	Dr. Felipe Pinto, Chile
10:00	Gran debate: Nivo o Pembrol en 1er línea de cáncer unión gastro-esofágica	Dr. Marcelo Garrido, Chile Dr. Guillermo Méndez, Argentina
10:30	Visita stands y café	
INMUNOTERAPIA CÁNCERES GASTROINTESTINALES 2		Presiden: Dres.: Jorge Madrid, Chile - Sebastián Mondaca, Chile.
11:00	Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.	Dr. Mariano Dioca, Argentina
11:15	Immunotherapy for Early-Stage hepatocellular carcinoma	Dr. Sebastián Mondaca, Chile
11:30	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.	Dr. Gerardo Arroyo, Argentina
11:45	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.	Dr. Fernando Chuecas, Chile
12:00	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC)	Dr. Daniel Alarcón, Ecuador
12:15	Phase III trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.	Dra. Adriana Della Valle, Uruguay
12:30	Gran Debate: En pacientes con cáncer de colon Et IV BRAF mutado y simultáneamente con MSI -H ¿Cuál es la mejor terapia? Inmunoterapia vs terapia de BRAF mutado (encorafenib.cetuximab)	Dr. Andrés Andrade, Ecuador Dr. Luis Ubillos, Uruguay
13:00 - 13:30	Bloque Simposio MSD "Impacto en el tratamiento en los pacientes de cáncer colorrectal metastásico, MSI-H y experiencia clínica."	Dr. Juan Manuel O'Connor, Argentina
FUNDAMENTOS DE INMUNOTERAPIA E INDICACIONES ACTUALES		Presiden: Dres.: Jaime de la Garza, México - Eduardo Richardet, Argentina
14:30	Introducción tratamiento del adenocarcinoma de pulmón	Dr. Eduardo Richardet, Argentina
14:45	Inmunoterapia en cáncer pulmonar escamoso	Dr. Luis Lara, México
15:00	Interacción entre radioterapia e inmunoterapia	Dr. Gustavo Ferraris, Argentina
15:15	Inmunoterapia en cáncer pulmón etapa III	Dr. Diego Kaen, Argentina
15:30	Atezolizumab en Cáncer de Pulmón	Dr. Suraj S. Samtani, Chile
15:45	Preguntas	Dr. Eduardo Richardet, Argentina
16:00	Visita stands y café	
INMUNOTERAPIA EN CÁNCER UROLÓGICO Y MELANOMA		Presiden: Dres.: Eva García, Chile - Francisco Gutiérrez, México
16:30	LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study	Dr. Suraj S. Samtani, Chile
16:45	Inmunoterapia en cáncer uroléital	Dr. Francisco Gutiérrez, México
17:00	Inmunoterapia en cáncer renal.	Dra. Pamela Salman, Chile
17:20	LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial	Dr. José L. González T, México
17:40	Melanoma y metástasis SNC.	Dr. Martín Richardet, Argentina
18:00	Inmunoterapia Adyuvante mama TN	Dr. Damián Hannonis, Chile-Argentina
18:20	Bloque Simposio GRUNENTHAL "Profilaxis antiemética en NVIQ: Enfoque en calidad de vida"	Dra. Paula Carrasco, Chile
18:50	Cierre	Dr. Jorge Gallardo, Chile Dr. Eduardo Richardet, Argentina